BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 32361788)

  • 1. A Novel DNA Aptamer Probe Recognizing Castration Resistant Prostate Cancer in vitro and in vivo Based on Cell-SELEX.
    Zhong J; Liu D; Yang Q; Ding J; Chen X
    Drug Des Devel Ther; 2024; 18():859-870. PubMed ID: 38524880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of novel cabazitaxel analogues.
    Ren S; Zhang M; Wang Y; Guo J; Wang J; Li Y; Ding N
    Bioorg Med Chem; 2021 Jul; 41():116224. PubMed ID: 34058663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small Mitochondria-Targeting Fluorophore with Multifunctional Therapeutic Activities against Prostate Cancer via the HIF1α/OATPs Pathway.
    Qin J; Zhang C; Zhao Y; Tan D; Wu P; Shui X; Qin W; Ge X; Shi C
    Mol Pharm; 2023 Dec; 20(12):6226-6236. PubMed ID: 37955533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Aktuelle Urol; 2024 Apr; 55(2):98. PubMed ID: 38537656
    [No Abstract]   [Full Text] [Related]  

  • 5. [Not Available].
    Aktuelle Urol; 2024 Apr; 55(2):96-98. PubMed ID: 38537655
    [No Abstract]   [Full Text] [Related]  

  • 6. A novel multi-functionalized multicellular nanodelivery system for non-small cell lung cancer photochemotherapy.
    Zhang Y; Xia Q; Wu T; He Z; Li Y; Li Z; Hou X; He Y; Ruan S; Wang Z; Sun J; Feng N
    J Nanobiotechnology; 2021 Aug; 19(1):245. PubMed ID: 34391438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer.
    Maines F; Caffo O; Veccia A; Trentin C; Tortora G; Galligioni E; Bria E
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):498-506. PubMed ID: 26318091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel.
    Fernández O; Afonso J; Vázquez S; Campos B; Lázaro M; León L; Antón Aparicio LM
    Anticancer Drugs; 2014 Mar; 25(3):237-43. PubMed ID: 24217332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The near-infrared fluorescent dye IR-780 was coupled with cabazitaxel for castration-resistant prostate cancer imaging and therapy.
    Zheng Y; Hou G; Zhang G; Lan T; Yuan J; Zhang L; Yan F; Wang F; Meng P; Dun X; Li X; Chen G; Zhu Z; Wei D; He W; Yuan J
    Invest New Drugs; 2020 Dec; 38(6):1641-1652. PubMed ID: 32361788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coupling the near-infrared fluorescent dye IR-780 with cabazitaxel makes renal cell carcinoma chemotherapy possible.
    Zheng Y; Lan T; Wei D; Zhang G; Hou G; Yuan J; Yan F; Wang F; Meng P; Yang X; Chen G; Zhu Z; Lu Z; He W; Yuan J
    Biomed Pharmacother; 2019 Aug; 116():109001. PubMed ID: 31146114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-assembled albumin nanoparticles for combination therapy in prostate cancer.
    Lian H; Wu J; Hu Y; Guo H
    Int J Nanomedicine; 2017; 12():7777-7787. PubMed ID: 29123392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.
    Thibault C; Eymard JC; Birtle A; Krainer M; Baciarello G; Fléchon A; Le Moulec S; Spaeth D; Laguerre B; Caffo O; Deville JL; Beuzeboc P; Hasbini A; Gross-Goupil M; Helissey C; Bennamoun M; Hardy-Bessard AC; Oudard S
    Eur J Cancer; 2018 Jul; 97():41-48. PubMed ID: 29636272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer.
    Zhou X; Zou L; Chen W; Yang T; Luo J; Wu K; Shu F; Tan X; Yang Y; Cen S; Li C; Mao X
    Pharmacol Res; 2021 Feb; 164():105305. PubMed ID: 33197601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.
    Delanoy N; Hardy-Bessard AC; Efstathiou E; Le Moulec S; Basso U; Birtle A; Thomson A; Krainer M; Guillot A; De Giorgi U; Hasbini A; Daugaard G; Bahl A; Chowdhury S; Caffo O; Beuzeboc P; Spaeth D; Eymard JC; Fléchon A; Alexandre J; Helissey C; Butt M; Priou F; Lechevallier É; Deville JL; Goupil MG; Morales R; Thiery-Vuillemin A; Gavrikova T; Barthelemy P; Sella A; Fizazi K; Baciarello G; Fererro JM; Laguerre B; Verret B; Hans S; Oudard S
    Eur Urol Oncol; 2018 Dec; 1(6):467-475. PubMed ID: 31158090
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.